AstraZeneca PLC
23 October 2003
AstraZeneca's third quarter and nine months results 2003
Reference today's release of the AstraZeneca third quarter and nine months
results at 11:00 BST, please note that the analyst teleconference is now
scheduled for 13:00BST, 08:00 EST, for which the numbers are in the UK: 0800 279
9640, for Europe +44 (0)20 7019 9504 and for the US: 1 866 850 2201 . These
numbers, as well as details of the replay facility available through Monday, 3
November 2003, are on the Investor Relations part of the AstraZeneca website at
www.astrazeneca.com.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.